Extension of Time to File SOU

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: LUMAKRAS (see, http://uspto.report/TM/90044720/mark.png)
SERIAL NUMBER: 90044720

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Amgen Inc., having an address of
      Trademark Operations - MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 804-447-3278
      Email: XXXX
Proposed: Amgen Inc., having an address of
      Trademark Operations - MS-28-5A
      One Amgen Center Drive
      Thousand Oaks, California 91320-1799
      United States
      Phone: 804-447-3278
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 11/24/2020.

For International Class 005:
Current identification: Pharmaceutical preparations for use in the prevention of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations for use in the treatment of amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amylodiosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      ELSA D. LEMOINE
      PRIMARY EMAIL FOR CORRESPONDENCE: elemoine@amgen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): tmops@amgen.com

Correspondence Information (proposed):
      Elsa D. Lemoine
      PRIMARY EMAIL FOR CORRESPONDENCE: elemoine@amgen.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): tmops@amgen.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Elsa D. Lemoine/      Date Signed: 04/02/2021
Signatory's Name: Lemoine, Elsa D.
Signatory's Position: Attorney of Record, California Bar member
Signatory's Phone: 805-447-3278
Signature method: Sent to third party for signature

PAYMENT: 90044720
PAYMENT DATE: 04/02/2021

Serial Number: 90044720
Internet Transmission Date: Fri Apr 02 13:32:47 ET 2021
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.X-2021040213324709
6446-90044720-770e8fb1468a70b0a438f62857
999b7326374cfca35c83adbb36446acae9f39c8-
DA-32451030-20210402074544430663